Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden
In this article, published in Future Oncology, researchers from Sweden and Switzerland have investigated the pattern of implementation of subcutaneous trastuzumab and the switching rate between the two formulations in a real-world setting using data from three nonacademic hospitals in Sweden.
Please sign in or register for FREE
Sign in to The Evidence Base®
Did you know?
Your The Evidence Base™ account also gives you access to communities on regenerative medicine, real-world evidence and drug discovery. Find out more>>